Biotechnology
CVS and Walgreens to start selling abortion pill mifepristone this month
A container holding boxes of mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women’s Clinic in Carbondale, Illinois, on April 20, 2023. Evelyn Hockstein | Reuters CVS and Walgreens will start selling the abortion pill mifepristone this month at certain pharmacy locations in states where it is legal to […]
Read More
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but the […]
Read More
Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs
Budrul Chukrut | Lightrocket | Getty Images Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street’s estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech […]
Read More
Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could […]
Read More
Novavax to settle dispute over canceled Covid vaccine purchase agreement
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a […]
Read More
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge […]
Read More
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters AbbVie on Tuesday said longtime executive Robert Michael will become the company’s new CEO, replacing Richard Gonzalez. Michael, who is AbbVie’s president and chief operating officer, will become the company’s second-ever CEO […]
Read More
Biden administration examining role of supply chain middlemen in generic drug shortages
A variety of generic pills and capsules. Nenov | Moment | Getty Images The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans’ prescriptions. The move follows an […]
Read More
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged […]
Read More
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a […]
Read More